Azitra Inc.
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Dermatology
Azitra is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome (NS), a rare, chronic skin disease with no approved treatment options. The ATR-12 program includes a Phase 1b clinical trial in adult NS patients. ATR-04, Azitra's additional advanced program, ATR-04, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products. Azitra is also developing its proprietary filaggrin protein and peptide technologies for the consumer, cosmeceutical market.
Company HQ City:
Branford
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2014
Lead Product in Development:
ATR-12
CEO
Francisco Salva
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
4
Exchange
NYSE
Ticker
AZTR
When you expect your next catalyst update?
August 2026
What is your next catalyst (value inflection) update?
ATR-12 and ATR-04 clinical data
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}